DYN Stock Price, Dyne Therapeutics Inc Quote, Chart

Market Summary

USD26.65+0.65

Market Closed

2.50%

DYN Stock Price

View Fullscreen

DYN RSI Chart

DYN Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-9.05

Price/Sales (Trailing)

254.52

Price/Free Cashflow

-10.56

DYN Price/Sales (Trailing)

DYN Profitability

Return on Equity

-53.84%

Return on Assets

-49.28%

Free Cashflow Yield

-9.47%

DYN Fundamentals

DYN Revenue

Revenue (TTM)

9.1M

Rev. Growth (Yr)

101.07%

Rev. Growth (Qtr)

71.4%

DYN Earnings

Earnings (TTM)

-257.4M

Earnings Growth (Yr)

-48.57%

Earnings Growth (Qtr)

1.48%

Breaking Down DYN Revenue

Last 7 days

1.5%

Last 30 days

3.1%

Last 90 days

15.3%

Trailing 12 Months

98.4%

How does DYN drawdown profile look like?

DYN Financial Health

Current Ratio

21.83

DYN Investor Care

Shares Dilution (1Y)

49.86%

Diluted EPS (TTM)

-3.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.1M	0	0	0
2023	4.2M	5.9M	7.2M	7.6M
2022	806.0K	1.0M	1.8M	2.9M
2021	190.0K	376.0K	560.0K	742.0K
2020	265.0K	240.0K	215.0K	0
2019	0	0	0	290.0K
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dyne Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	farwell wildon	sold	-26,347	25.58	-1,030	chief medical officer
Mar 11, 2024	farwell wildon	sold	-40,734	25.7	-1,585	chief medical officer
Mar 11, 2024	high susanna gatti	sold	-58,904	25.7	-2,292	chief operating officer
Mar 11, 2024	scalzo richard william	sold	-67,541	25.2775	-2,672	svp, head of finance & admin.
Mar 11, 2024	brumm joshua t	sold	-1,704,140	25.6698	-66,387	ceo & president
Mar 11, 2024	beskrovnaya oxana	sold	-53,481	25.7	-2,081	chief scientific officer
Mar 11, 2024	brumm joshua t	acquired	277,000	5.54	50,000	ceo & president
Mar 11, 2024	mcneill jonathan	sold	-499,842	25.5008	-19,601	chief business officer
Mar 11, 2024	mcneill jonathan	acquired	98,750	5.54	17,825	chief business officer
Mar 08, 2024	scalzo richard william	sold	-2,261,470	26.2193	-86,252	svp, head of finance & admin.

Which funds bought or sold DYN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CITIGROUP INC	added	319	7,568,270	8,520,610	0.01%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-94.6	-925,159	120,487	-%
May 10, 2024	CREDIT SUISSE AG/	added	35.46	675,703	1,032,910	-%
May 10, 2024	VANGUARD GROUP INC	added	47.67	66,685,000	97,669,300	-%
May 10, 2024	BlackRock Inc.	added	42.27	102,634,000	153,023,000	-%
May 10, 2024	JPMORGAN CHASE & CO	added	31.07	991,840	1,543,560	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	45,424	45,424	-%
May 10, 2024	LPL Financial LLC	new	-	429,086	429,086	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	53.17	393,293	566,579	-%
May 10, 2024	Campbell & CO Investment Adviser LLC	added	104	826,184	1,072,230	0.09%

Are Funds Buying or Selling DYN?

Are funds buying DYN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DYN

No. of Funds

Unveiling Dyne Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 04, 2024	ra capital management, l.p.	6.4%	5,213,661	SC 13G
Feb 14, 2024	deep track capital, lp	3.26%	2e+06	SC 13G/A
Feb 14, 2024	citadel advisors llc	5.0%	6	SC 13G/A
Feb 12, 2024	mpm bioventures 2018, l.p.	4.0%	3,216,844	SC 13G/A
Feb 09, 2024	atlas venture fund xi, l.p.	9.0%	7,326,117	SC 13G/A
Jan 29, 2024	blackrock inc.	6.2%	3,788,682	SC 13G
Jan 19, 2024	deep track capital, lp	5.55%	4,500,000	SC 13G
Jan 19, 2024	deep track capital, lp	3.26%	2e+06	SC 13G/A
Feb 14, 2023	deep track capital, lp	5.15%	2,684,200	SC 13G/A
Feb 14, 2023	logos global management lp	4.1%	2,150,000	SC 13G/A

Recent SEC filings of Dyne Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	S-8	Employee Benefits Plan
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	SC 13G	Major Ownership Report
Apr 04, 2024	3/A	Insider Trading
Apr 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Dyne Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Dyne Therapeutics Inc News

Latest updates

Dyne Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Revenue	71.4%	3,002,000	1,751,500	2,189,000	2,207,000	1,493,000	1,342,500	903,000	441,000	230,000	182,000	184,000	210,000	166,000	-	-	24,000	67,000	110,000	-
Operating Expenses	2.2%	69,157,000	67,688,500	62,273,000	66,736,000	45,464,000	40,145,000	42,279,000	52,755,000	35,783,000	51,960,000	42,766,000	30,165,000	25,134,000	13,520,000	8,675,000	7,853,000	-	3,629,000	-
S&GA Expenses	-100.0%	-	8,844,000	7,022,000	7,606,000	7,928,000	6,955,000	7,609,000	6,091,000	7,547,000	9,659,000	6,256,000	6,293,000	6,509,000	3,841,000	1,341,000	1,764,000	-	647,000	-
R&D Expenses	-24.3%	44,539,000	58,844,500	55,251,000	59,130,000	37,536,000	33,190,000	34,670,000	46,664,000	28,236,000	42,301,000	36,510,000	23,872,000	18,625,000	9,679,000	7,334,000	6,089,000	-	2,982,000	-
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	140	122	180	200	1,637	818	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-	-	-	-960	-832	-1,233	-1,372	-11,208	-5,604	-	-	-
Net Income	1.5%	-65,649,000	-66,638,000	-60,210,000	-64,902,000	-44,187,000	-38,827,000	-41,385,000	-52,304,000	-35,583,000	-51,786,000	-42,582,000	-29,955,000	-24,968,000	-13,920,000	-8,982,000	-7,886,000	-5,403,500	-5,871,000	-
Net Income Margin	8.9%	-28.13	-30.88	-28.78	-31.84	-42.28	-57.64	-103	-175	-198	-201	-225	-259	-	-	-	-	-	-	-
Free Cashflow	-124.4%	-78,728,000	-35,088,000	-50,769,000	-55,892,000	-47,138,000	-29,711,000	-43,691,000	-31,170,000	-52,140,000	-30,058,000	-27,833,000	-46,888,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	216.4%	522	165	205	251	289	306	300	340	388	426	467	467	492	353	381	-	-	-	-
Current Assets	277.3%	488	129	168	213	249	266	258	298	344	382	425	461	487	349	380	-	-	15.00	8.00
Cash Equivalents	123.7%	272	122	130	168	181	172	145	136	148	201	229	258	311	301	380	-	-	15.00	8.00
Net PPE	-4.2%	5.00	5.00	5.00	5.00	6.00	6.00	6.00	5.00	6.00	5.00	3.00	3.00	2.00	2.00	1.00	-	-	1.00	0.00
Liabilities	-40.1%	44.00	74.00	53.00	45.00	47.00	54.00	50.00	53.00	51.00	57.00	53.00	15.00	13.00	11.00	15.00	11.00	6.00	2.00	4.00
Current Liabilities	-56.2%	22.00	51.00	30.00	20.00	22.00	28.00	23.00	26.00	23.00	29.00	23.00	-	-	11.00	5.00	-	-	2.00	1.00
Shareholder's Equity	423.7%	478	91.00	152	207	242	252	250	287	336	368	414	453	478	342	367	-	8.00	14.00	-
Retained Earnings	-10.4%	-698	-632	-565	-505	-440	-396	-357	-316	-264	-228	-176	-134	-104	-79.18	-50.53	-	-	-19.75	-4.89
Additional Paid-In Capital	62.5%	1,176	724	718	713	683	650	608	605	601	597	591	587	582	422	417	-	-	6.00	0.00
Shares Outstanding	41.7%	87.00	61.00	61.00	61.00	58.00	56.00	52.00	52.00	52.00	52.00	51.00	50.00	-	-	-	-	-	-	-
Float	-	-	-	-	504	-	-	-	216	-	-	-	-	-	-	-	629	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-124.4%	-78,537	-35,006	-50,602	-55,642	-46,908	-29,192	-42,805	-30,909	-50,739	-28,068	-26,952	-46,150	-18,393	-20,036	-11,886	-7,298	-7,288	-	-	-
Share Based Compensation	247.4%	19,906	5,730	4,876	4,749	4,617	3,832	3,827	3,031	4,488	6,013	3,638	4,239	3,652	4,215	2,235	75.00	66.00	-	-	-
Cashflow From Investing	-786.5%	-179,837	26,196	12,821	17,232	27,062	19,237	51,658	18,443	-2,136	-235	-2,848	-6,434	-128,375	-45,223	-156	-71.00	-211	-	-	-
Cashflow From Financing	277715.0%	408,388	147	454	24,906	28,815	37,203	70.00	99.00	18.00	89.00	457	25.00	157,250	-11,194	379,976	-	11,908	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DYN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 44,539	$ 37,536
General and administrative	24,618	7,928
Total operating expenses	69,157	45,464
Loss from operations	(69,157)	(45,464)
Other income (expense):
Interest income	3,002	1,493
Other income (expense), net	506	(216)
Total other income (expense), net	$ 3,508	$ 1,277
Net loss per share - basic	$ (0.81)	$ (0.78)
Net loss per share - diluted	$ (0.81)	$ (0.78)
Weighted average common shares outstanding, basic	81,043,741	56,325,864
Weighted average common shares outstanding, diluted	81,043,741	56,325,864
Comprehensive loss:
Net Income (Loss)	$ (65,649)	$ (44,187)
Other comprehensive loss:
Unrealized (losses) gains on marketable securities, net	(132)	368
Comprehensive loss	$ (65,781)	$ (43,819)

DYN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 272,035	$ 121,626
Marketable securities	181,512	1,474
Prepaid expenses and other current assets	34,594	6,275
Total current assets	488,141	129,375
Property and equipment, net	4,578	4,780
Right-of-use assets	27,640	28,612
Restricted cash	1,920	2,315
Total assets	522,279	165,082
Current liabilities:
Accounts payable	7,214	22,936
Accrued expenses and other current liabilities	10,393	23,439
Lease liabilities	4,756	4,720
Total current liabilities	22,363	51,095
Lease liabilities, net of current portion	21,861	22,695
Total liabilities	44,224	73,790
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 87,089,649 and 61,468,743 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	9	6
Additional paid-in capital	1,176,337	723,796
Accumulated other comprehensive loss	(132)	0
Accumulated deficit	(698,159)	(632,510)
Total stockholders’ equity	478,055	91,292
Total liabilities and stockholders’ equity	$ 522,279	$ 165,082

About Dyne Therapeutics Inc

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Joshua T. Brumm
WEBSITE	dyne-tx.com
INDUSTRY	Biotechnology
EMPLOYEES	134

Dyne Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Dyne Therapeutics Inc? What does DYN stand for in stocks?

DYN is the stock ticker symbol of Dyne Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dyne Therapeutics Inc (DYN)?

As of Mon May 13 2024, market cap of Dyne Therapeutics Inc is 2.33 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DYN stock?

You can check DYN's fair value in chart for subscribers.

What is the fair value of DYN stock?

You can check DYN's fair value in chart for subscribers. The fair value of Dyne Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dyne Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DYN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dyne Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DYN is over valued or under valued. Whether Dyne Therapeutics Inc is cheap or expensive depends on the assumptions which impact Dyne Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYN.

What is Dyne Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, DYN's PE ratio (Price to Earnings) is -9.05 and Price to Sales (PS) ratio is 254.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYN PE ratio will change depending on the future growth rate expectations of investors.